The effects of disease-modifying therapies in SMA-5q type 1 and the importance of early diagnosis of the disease
- Alternative title
-
Os efeitos das terapias modificadoras da doença na atrofia muscular espinhal 5q do tipo 1 e a importância do diagnóstico precoce da doença
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
The effects of disease-modifying therapies in SMA-5q type 1 and the importance of early diagnosis of the disease ; volume:82 ; number:11 ; year:2024 ; pages:001-002
Arquivos de neuro-psiquiatria ; 82, Heft 11 (2024), 001-002
- Contributor
-
Zanoteli, Edmar
- DOI
-
10.1055/s-0044-1800927
- URN
-
urn:nbn:de:101:1-2502061052195.109127869321
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zanoteli, Edmar
Other Objects (12)
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Outcome of MS relapses in the era of disease-modifying therapy
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Amisulpride as a potential disease-modifying drug in the treatment of tauopathies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Outcome of MS relapses in the era of disease-modifying therapy
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Amisulpride as a potential disease-modifying drug in the treatment of tauopathies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Outcome of MS relapses in the era of disease-modifying therapy
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Amisulpride as a potential disease-modifying drug in the treatment of tauopathies
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin